Verastem (VSTM) Revenue (2018 - 2026)

Verastem (VSTM) posted quarterly Revenue of $18.7 million for Q1 2026, up 6.48% quarter-over-quarter from $17.5 million in Q4 2025.

Verastem (VSTM) Revenue (2018 - 2026) Analysis & Trends

Verastem's Revenue history runs 8 years deep, the most recent figure standing at $18.7 million for Q1 2026.

In Q1 2026, Revenue changed N/A year-over-year to $18.7 million; the TTM figure through Mar 2026 stood at $49.6 million (changed N/A YoY), while the FY2025 annual figure was $30.9 million, up 209.14% from the prior year.
Revenue for Q1 2026 stood at $18.7 million, up from $17.5 million in the prior quarter.
The five-year high for Revenue was $18.7 million in Q1 2026, with the low at $2.1 million in Q2 2025.
The 4-year median for Revenue is $10.6 million (2024), against an average of $10.4 million.
The sharpest annual moves came in 2022 and 2025: Revenue surged 158.05% in 2022, then tumbled 78.63% in 2025.
Verastem's Revenue stood at $2.6 million in 2022, then soared by 285.21% to $10.0 million in 2024, then surged by 75.35% to $17.5 million in 2025, then grew by 6.48% to $18.7 million in 2026.
Business Quant data shows VSTM's Revenue at $18.7 million in Q1 2026, $17.5 million in Q4 2025, and $11.2 million in Q3 2025.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Revenue (Qtr)
1	Vertex Pharmaceuticals	128.13 Bn	120.28 Bn	2.84 Bn	3.33 Bn
2	Regeneron Pharmaceuticals	112.33 Bn	104.33 Bn	3.93 Bn	4.29 Bn
3	Argenx Se	53.24 Bn	48.05 Bn	1.41 Bn	1.56 Bn
4	Revolution Medicines	43.64 Bn	43.64 Bn	-	-
5	BeOne Medicines	39.27 Bn	34.17 Bn	1.53 Bn	1.71 Bn
6	MindWalk Holdings	35.32 Bn	35.31 Bn	1.82 Bn	3,001.92
7	Royalty Pharma	33.72 Bn	35.84 Bn	-	674.14 Mn
8	Alnylam Pharmaceuticals	30.58 Bn	27.27 Bn	992.69 Mn	1.29 Bn
9	Insmed	27.01 Bn	25.85 Bn	358.27 Mn	425.49 Mn
10	Verastem	595.37 Mn	459.02 Mn	36.32 Mn	40.08 Mn

Download Data